Open company graph database — free web & API
Login

Kyowa Hakko Kirin Co., Ltd.

協和醗酵キリン株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
5,161
Related companies
1
§01

Basic information

BASIC
Head office
1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, Otemachi Financial City Gran Cube
Chief executive
Abdul Malik
Capital
26,745,000,000 JPY (267 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
5,161 people
Start date
1949-07-01
End date
§02

Websites

1 DOMAINS
§03

Business

0
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
協和キリングループ
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

32 EVENTS

Kirin Brewery Co., Ltd. was established.Sources

Kyowa Hakko Co., Ltd. was founded.Sources

Streptomycin manufacturing technology was introduced from Merck in the United States, and the first mass production of streptomycin in Japan was achieved. It contributed to the eradication of tuberculosis. (Initiation of pharmaceutical business activities)Sources

Successfully isolated mitomycin C, an antitumor agent, and industrialized it. Invented the first L-glutamic acid production technology using fermentation, pioneering the large-scale amino acid fermentation industry.Sources

Released the antitumor agent "Mitomycin" and the antibiotic "Spiramycin."Sources

Released the antitumor agent "5-FU" and the antibiotic formulation "Acetylspiramycin."Sources

Released the antitumor agent "Roinease®."Sources

Commenced comprehensive research aimed at pharmaceutical development of erythropoietin.Sources

Supported the establishment of the Lahoja Allergy Immunology Institute in the United States.Sources

Released the renal anemia treatment drug "Espo®" (EPO formulation).Sources

Released the neutropenia treatment drug "Gran®" (G-CSF formulation). Released the hypertension and angina treatment drug "Conir®."Sources

Established technology for producing fully human antibodies.Sources

Released the allergy treatment drug "Alerock® tablets."Sources

Established the antibody pharmaceutical business company "BioWa, Inc." in the United States.Sources

Released the anti-allergy eye drop "Patanol® eye drops."Sources

With the introduction of Kirin Beer Co., Ltd.'s pure holding company structure, "Kirin Pharma Co., Ltd." was founded. Released the sustained-release erythropoietin-stimulating agent "Nesup®." Established the new technology "COMPLEGENT®" to enhance antibody pharmaceutical activity.Sources

Released the secondary hyperparathyroidism treatment drug "Regpar® tablets." Split the biochemicals business and established Kyowa Hakko Bio Co., Ltd. Founded Kyowa Hakko Kirin Co., Ltd.Sources

Established "Our Vision."Sources

Released the platelet-stimulating agent/thrombopoietin receptor agonist "Romiplate® subcutaneous 250 µg formulation." Acquired the UK company ProStrakan.Sources

Founded the joint venture "Kyowa Kirin Fujifilm Biologics Co., Ltd." for development, manufacturing, and sales of biosimilar drugs with Fujifilm. Released the adult T-cell leukemia/lymphoma (ATL) treatment drug "Poteligo® IV infusion 20 mg."Sources

New Parkinson's disease treatment "Nourialist® 20mg tablets" released.Sources

UK-based ProStrakan acquired Archimedes. Sustained-release G-CSF product "GiraSTA® subcutaneous 3.6mg" launched.Sources

Kyowa Kirin brand unified. Domestic sales of psoriasis treatment Lumisef® begin.Sources

Kohwa Kirin Frontier Co., Ltd. established.Sources

X-linked hypophosphatemia treatment Crysvita® approved in Europe and the U.S. Cystic papilloma and Cezary syndrome treatment Poteligeo® approved in Europe and the U.S.Sources

Company renamed to Kohwa Kirin Co., Ltd. Kyowa KIRIN FGF23-related hypophosphatemic disease treatment Crysvita® launched in Japan. Parkinson's disease treatment Nourianz™ launched in the U.S.Sources

Cystic papilloma and Cezary syndrome treatment Poteligeo® launched in Europe. Crysvita® received additional indication approval for tumor-induced osteomalacia (TIO) in the U.S.Sources

New vision for 2030 formulated, aiming for life-changing value. Joint development and sales agreement with Amgen for human anti-OX40 monoclonal antibody KHK4083. Expressed support for TCFD recommendations.Sources

Global DE&I declaration formulated, aiming for 40% female leadership by 2030. GiraSTA® subcutaneous 3.6mg body pod launched in Japan. Q-TOWER bio‑pharmaceutical analysis facility completed at the Hirosaki plant.Sources

Domestic approval for high‑phosphatemia treatment Fozebel® obtained. Acquisition of UK-based Orchard Therapeutics plc, a company with hematopoietic stem cell gene‑therapy technology, announced.Sources

Hematopoietic stem cell gene‑therapy Lenmeldy™ (atidarsagene autotemcel) approved by U.S. FDA and launched. New biopharmaceutical plant in North Carolina, USA, construction decided. Strategic partnership with Kura Oncology for global development and sales of the acute leukemia inhibitor ziftomenib.Sources

HB7 building constructed at Hirosaki plant to manufacture biopharmaceutical APIs, strengthening global production capacity and bio‑human resource development. Adult acute myeloid leukemia drug KOMZIFTI™ (ziftomenib) FDA approved and launched in the U.S.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑